Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on ...
I maintain my Buy rating on Rhythm Pharmaceuticals due to its leadership in rare genetic obesity treatments. The company’s innovative therapies address significant unmet needs, supporting long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback